PROSCAR Drug Patent Profile

When do Proscar patents expire, and what generic alternatives are available?

Proscar is a drug marketed by Organon and is included in one NDA.

The generic ingredient in PROSCAR is finasteride. There are fourteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the finasteride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Proscar

A generic version of PROSCAR was approved as finasteride by DR REDDYS LABS INC on July 28^th, 2006.

Summary for PROSCAR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	86
Clinical Trials:	22
Drug Prices:	Drug price information for PROSCAR
What excipients (inactive ingredients) are in PROSCAR?	PROSCAR excipients list
DailyMed Link:	PROSCAR at DailyMed

See drug prices for PROSCAR

Recent Clinical Trials for PROSCAR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Baylor College of Medicine	Phase 3
Astellas Pharma Korea, Inc.	Phase 4
Seoul National University Hospital	Phase 4

See all PROSCAR clinical trials

Pharmacology for PROSCAR

Drug Class	5-alpha Reductase Inhibitor
Mechanism of Action	5-alpha Reductase Inhibitors

US Patents and Regulatory Information for PROSCAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	PROSCAR	finasteride	TABLET;ORAL	020180-001	Jun 19, 1992	AB	RX	Yes	Yes

Expired US Patents for PROSCAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	PROSCAR	finasteride	TABLET;ORAL	020180-001	Jun 19, 1992	4,377,584
Organon	PROSCAR	finasteride	TABLET;ORAL	020180-001	Jun 19, 1992	4,760,071
Organon	PROSCAR	finasteride	TABLET;ORAL	020180-001	Jun 19, 1992	6,046,183
Organon	PROSCAR	finasteride	TABLET;ORAL	020180-001	Jun 19, 1992	5,942,519
Organon	PROSCAR	finasteride	TABLET;ORAL	020180-001	Jun 19, 1992	5,886,184

International Patents for PROSCAR

See the table below for patents covering PROSCAR around the world.

Country	Patent Number	Title	Estimated Expiration
Bulgaria	99637
Romania	115164	17 BETA-(N-TERT-BUTILCARBAMOIL)-4-AZA- 5ALFA-ANDROST-1-EN-3-ONA SI PROCEDEE PENTRU PREPARAREA ACESTEIA (17BETA-(N-TERTIARY-BUTYLCARBAMOYL)-4-AZA- 5ALPHA-ANDROST-1-EN-3-ONE AND PROCESSES FOR PREPARING SAID COMPOUND)
Australia	2748192
Israel	125769	POLYMORPHIC FORM OF FINASTERIDE AND ITS PRODUCTION
European Patent Office	0200443	LIPOXYGENASE INHIBITORS
Portugal	100256	METODO PARA O TRATAMENTO DA HIPERPLASIA PROSTATICA BENIGNA
Japan	H03163093	17 BETA-ACYL-4-AZA-5 ALPHA-ANDROST-1-ENE- 3-ONE AS 5 ALPHA-REDUCTASE INHIBITOR

Supplementary Protection Certificates for PROSCAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0155096	93C0055	Belgium		PRODUCT NAME: FINASTERIDUM; NAT. REG..: 922 IS 151 F 3 19930125; FIRST REG.: GB PL 0025/0279 19920527
0155096	SPC/GB93/006	United Kingdom		SPC/GB93/006:, EXPIRES: 20070526

PROSCAR (Finasteride) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

PROSCAR, a 5-alpha-reductase inhibitor developed by Merck & Co., has established a significant market presence for the treatment of benign prostatic hyperplasia (BPH). Its therapeutic mechanism involves inhibiting the conversion of testosterone to dihydrotestosterone (DHT), thereby reducing prostate size and alleviating BPH symptoms.

What is PROSCAR's Current Market Position?

PROSCAR is a mature pharmaceutical product with a well-defined market share primarily within the BPH therapeutic area. Its efficacy in reducing prostate volume and improving urinary flow rates has solidified its position as a cornerstone treatment.

Key Market Indicators for PROSCAR

• Indication: Benign Prostatic Hyperplasia (BPH).
• Mechanism of Action: Type II 5-alpha-reductase inhibitor.
• Dosage Form: Oral tablet.
• Therapeutic Class: Urologicals, Endocrine Agents.
• Market Status: Generic availability of finasteride has led to a highly competitive landscape.
• Primary Competitors (Generic Finasteride): Numerous manufacturers offer generic versions of finasteride, impacting PROSCAR's brand-driven revenue.
• Key Differentiating Factor (Historical): PROSCAR was the first 5-alpha-reductase inhibitor approved for BPH, giving it a significant first-mover advantage.

What are PROSCAR's Patent Expirations and Generic Impact?

PROSCAR's core patents have long expired, opening the door for extensive generic competition. This has fundamentally reshaped its market dynamics and financial trajectory.

Patent Expiration Timeline and Generic Entry

• Original Patent Filing (US): 1977
• Original US Approval for BPH: December 1992
• Key Compound Patents: Expired in the early 2000s.
• Generic Finasteride Entry: Commenced in the mid-2000s, with numerous manufacturers launching low-cost generic alternatives.
• Impact of Generic Entry: Significant price erosion of the branded PROSCAR product and a shift in market share towards generics.

What is PROSCAR's Historical Financial Performance?

Merck's financial reporting historically included PROSCAR sales as part of its broader urology portfolio. While specific historical sales figures for PROSCAR alone are not consistently broken out in recent reports due to the dominance of generic competition, its peak sales and subsequent decline illustrate the typical lifecycle of a patented drug.

Indicative Historical Sales Trends (Estimates based on industry reports and Merck's disclosures)

Year (Approximate)	Peak Branded Sales (USD Millions)	Post-Generic Entry Sales Trend
Early 2000s	$500 - $800	Stable to slight decline
Mid-2000s onwards	Significant and ongoing decline	Steep decline due to generics

Note: These figures represent estimated peak branded sales before widespread generic competition. Current sales for the branded PROSCAR are minimal due to generic availability and price competition.

What is PROSCAR's Current Financial Trajectory and Revenue Generation?

The financial trajectory for branded PROSCAR is characterized by a substantial decline from its peak. Revenue generation is now primarily driven by generic finasteride manufacturers. Merck's focus has shifted to other therapeutic areas and newer product launches.

Current Revenue Landscape

• Branded PROSCAR Sales: Negligible. Merck continues to market PROSCAR, but its market share is minimal.
• Generic Finasteride Market: Highly fragmented with numerous manufacturers. The market is driven by price competition and volume.
• Market Value of Generic Finasteride: While specific market value is difficult to isolate globally for the BPH indication alone, the overall finasteride market (including hair loss treatment, Propecia) is substantial. For BPH, the market is largely commoditized.
• Key Revenue Drivers for Generic Manufacturers: Volume sales at competitive price points.
• Cost of Goods: Significantly lower for generic manufacturers compared to the development and marketing costs of the original branded drug.

What are the Market Dynamics for Finasteride (BPH Indication)?

The BPH market for finasteride is characterized by intense price competition and a high volume of generic prescriptions. Prescribers and payers often favor generic alternatives due to cost-effectiveness.

Competitive Landscape for Finasteride in BPH

• Market Dominated By: Generic finasteride.
• Pricing: Low, driven by competition. A typical prescription for generic finasteride is priced significantly lower than its branded counterpart would have been.
• Prescriber Behavior: While clinical efficacy is recognized, cost considerations often lead to generic prescribing.
• Payer Influence: Pharmacy benefit managers (PBMs) and insurance companies often mandate or strongly encourage the use of generics.
• Alternative Treatments: Alpha-blockers (e.g., tamsulosin), other 5-alpha-reductase inhibitors (e.g., dutasteride), and surgical interventions compete for market share.
• Therapeutic Guidelines: Clinical practice guidelines continue to recognize finasteride as a valid treatment option for BPH, supporting its ongoing use in generic form.

What are the Future Market Prospects for PROSCAR and Finasteride?

The future market for PROSCAR (branded) is limited. The market for generic finasteride in BPH will likely remain stable, driven by the ongoing prevalence of BPH and the cost-effectiveness of generic options.

Future Market Considerations

• Branded PROSCAR: Minimal growth prospects. Its role is largely historical.
• Generic Finasteride (BPH):
  • Demand: Steady demand due to the aging population and the continued efficacy of finasteride for BPH.
  • Competition: Expected to remain intense, with ongoing price pressure.
  • Innovation: Limited opportunities for significant innovation within the generic BPH space for finasteride itself. Focus will be on supply chain efficiency and cost reduction.
  • Regulatory Landscape: No significant shifts expected that would dramatically alter the generic market.
• Potential for New Indications or Formulations: While finasteride is primarily known for BPH and hair loss, research into other potential therapeutic applications could emerge, but this is speculative and not directly tied to the PROSCAR brand.

Key Takeaways

PROSCAR, originally a significant revenue driver for Merck, has transitioned into a mature product whose market is now dominated by generic finasteride. Patent expirations have led to substantial price erosion and a highly competitive landscape for generic manufacturers. The branded PROSCAR product has negligible market share and minimal financial contribution. The future market for BPH treatment with finasteride rests with its generic versions, which are expected to maintain steady demand due to BPH prevalence and cost-effectiveness, while facing persistent price competition.

Frequently Asked Questions

1. What is the primary medical indication for PROSCAR? PROSCAR is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH).

2. When did the key patents for PROSCAR expire? The core compound patents for finasteride, the active ingredient in PROSCAR, expired in the early 2000s.

3. Who are the main competitors to branded PROSCAR? The main competitors are the numerous manufacturers offering generic versions of finasteride.

4. What is the current pricing strategy for generic finasteride? Generic finasteride is priced competitively, with market pricing driven by volume and intense price competition among manufacturers.

5. Does Merck continue to invest heavily in the PROSCAR brand? Merck's investment focus has shifted away from the branded PROSCAR. The company's R&D and commercial strategies now prioritize newer therapeutic areas and innovative products.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Prescription Drug Information. Retrieved from FDA.gov. (Specific approval dates and product information are available through FDA databases). [2] Merck & Co., Inc. (Various Years). Annual Reports. (Financial disclosures provide historical context for product performance, though specific PROSCAR sales are not consistently detailed post-generic entry). [3] Industry Analyst Reports. (Various Dates). Pharmaceutical Market Research on Urology and BPH Treatments. (Proprietary market data and analyses).